different coronary pathophysiological substrates with additive impact on prognosis.
The aim of this study was to evaluate the combined effect of coronary atherosclerosis, assessed by computed tomographic angiography (CTA), and myocardial ischemia, assessed by stress imaging, on cardiac release of hscTnT and NT-proBNP in patients with stable CAD enrolled in the Evaluation of Integrated Cardiac Imaging (EVINCI) study. 8 
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Baseline Clinical Characteristics of Study Population
In the entire population (Figure 1 ), the median value (25-75 percentile) of plasma hs-cTnT was 6.17 (4.16-9 .09) ng/L and of NT-proBNP was 61.66 (31. .60) ng/L.
Only 34 (9%) and 77 (20%) patients had plasma levels of hs-cTnT and NT-proBNP exceeding the upper limits of the normality ranges (14 and 157 ng/L, respectively). The median values were used as cut-off points to divide patients into groups with low (<median) or high (≥median) concentrations of hs-cTnT and NT-proBNP. Baseline characteristics of the patients are compared between groups in Table 1 . Patients with high levels of hs-cTnT were older and had higher frequency of male sex, diabetes mellitus, and hypertension than patients with low levels of hs-cTnT. Patients with high levels of NT-proBNP were also older than patients with low levels of NT-proBNP but showed a lower frequency of male sex and diabetes mellitus and a lower LV ejection fraction (LVEF). No differences in type of symptoms were observed among patients with high or low hs-cTnT or NT-proBNP. The metabolic and inflammatory profile was altered in patients with high levels of hs-cTnT but not in those with high NT-proBNP levels.
Coronary Atherosclerosis and Myocardial Ischemia
Results from CTA (coronary anatomy, plaque characterization, and risk scores) and stress imaging (myocardial ischemia) are compared between groups of patients with high or low hs-cTnT or NT-proBNP in Table 2 .
Biomarker levels were associated with the severity and the number of coronary lesions. Patients with high hs-cTnT as well as patients with high NT-proBNP showed a higher frequency of obstructive coronary lesions as compared with patients with low hs-cTnT and NT-proBNP who showed a higher frequency of normal coronary arteries. Figure 2 illustrates the increase of hs-cTnT and NT-proBNP plasma levels according to the presence of nonobstructive or obstructive coronary lesions (Figure 2A ) or the number of coronary lesions (either obstructive or nonobstructive; Figure 2B ).
The 2 biomarkers were differently associated with plaque types. Patients with high hs-cTnT, but not patients with high NT-proBNP, showed more frequently calcified or mixed plaques than patients with low hs-cTnT and had a higher number of mixed plaques. The CTA risk score was significantly higher in patients with high hs-cTnT or high NT-proBNP, whereas coronary artery calcium score was significantly higher only in patients with high hs-cTnT (Table 2) .
Both patients with high hs-cTnT and high NT-proBNP had a higher frequency and larger extent of myocardial ischemia (Table 2) .
Integrated Effects of Coronary Atherosclerotic Burden and Myocardial Ischemia on Circulating hs-cTnT and NT-proBNP Levels and LV Function
Univariate (Table I in the online-only Data Supplement) and multivariate linear regression models were used to identify the independent predictors of elevated levels of hs-cTnT and NT-proBNP (Table 3) . Age, male sex, and CTA risk score were independent predictors of increased hs-cTnT levels. Age, female sex, lower LVEF, and the presence of ischemia were independent predictors of increased NT-proBNP levels. In a sex-and age-specific analysis, CTA risk score was significantly related with hs-cTnT levels in both men and women >60 years, whereas the presence of ischemia was related with increased NT-proBNP in males independently of age (Tables  II and III in the online-only Data Supplement). Patients were subdivided into groups according to the absence/presence of coronary atherosclerosis (CAD) and ischemia, either alone or combined. Patients with CAD with/without ischemia showed significantly higher levels of hs-cTnT than patients without CAD, whereas only patients with CAD plus ischemia had significantly higher levels of NT-proBNP as compared with all the other groups ( Figure 3A) . Similar results were obtained by hybrid imaging analysis. Patients with an inducible perfusion defect in a territory subtended by a stenotic coronary artery on CTA (matched) were compared with patients with all other combinations of pathological findings (unmatched) and with normals. As compared with normals, NT-proBNP levels were significantly increased only in patients with matched findings, whereas hs-cTnT levels were significantly elevated in both patients with matched and mismatched findings ( Figure 3B ). Continuous variables are presented as mean±standard error or median [25-75 percentile] , categorical variables as absolute N and (%). ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blockers; CAD, coronary artery disease; CV, cardiovascular; HDL, highdensity lipoprotein; hs-CRP, high-sensitivity C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; LDL, low-density lipoprotein; LV, left ventricle; LVEF, left ventricular ejection fraction; and NT-proBNP, N terminal pro brain natriuretic peptide.
LVEF and NT-proBNP were linearly correlated in the whole population (P=0.002). Interestingly, only patients with coronary atherosclerosis and myocardial ischemia had significantly decreased LVEF values as compared with all the other patient groups (Figure 4) .
Discussion
This is the first study which evaluated the relative effects of both coronary atherosclerosis and myocardial ischemia on cardiac release of hs-cTnT and NT-proBNP in patients with stable CAD. The main findings can be summarized as follows: 1. Circulating levels of hs-cTnT are related to the presence and extent of coronary lesions as well as coronary plaque composition; in addition, the global coronary atherosclerotic burden, as assessed by the CTA risk score, is a predictor of hs-cTnT plasma levels independent of myocardial ischemia. 2. Circulating levels of NT-proBNP are mainly related with the presence of functionally relevant coronary disease causing myocardial ischemia.
Cardiac troponins are the marker of choice for the detection of myocardial injury and the diagnosis of myocardial infarction. 2 Over the past 10 years, cardiac troponin assays have been improved in analytic sensitivity and precision, thereby allowing the measurement of cardiac troponin in nearly all healthy subjects. 9 Because of the significant biological variability of this biomarker, individual measurements can be more relevant than population reference values. 10 In stable CAD, the release of cardiac troponin T has been linked to the extent of coronary atherosclerosis, [3] [4] [5] 11 although the relationship with transient myocardial ischemia is debated. 12, 13 In the current study, only the global atherosclerotic burden, as assessed by the CTA risk score, was an independent predictor of hs-cTnT levels at multivariate analysis. This association was specifically evident in older patients, independently of sex. Patients with coronary atherosclerosis showed significantly higher levels of hs-cTnT compared with patients without, independent of the presence of myocardial ischemia (Figure 3) .
The mechanisms of hs-cTnT elevation in patients with stable CAD, who had no occurrence of acute events with myocyte necrosis, are not fully understood. Consistently with the present findings, it has been hypothesized that at the site of atherosclerotic lesions, dislodging and erosion processes could cause microembolization of atherosclerotic and thrombotic material into the microcirculation. 11, 14 It has been reported that chronic clinically silent rupture of noncalcified plaques with subsequent microembolization may be a potential source of troponin elevation. 15 These findings are in line with the results from the present study, in which the patients with higher coronary atherosclerotic burden and mixed plaques showed higher levels of hs-cTnT than the patients without. Mechanisms which link microembolization with myocardial damage and troponin release involve tumor necrosis factor-α and nitric oxide, which may trigger apoptotic pathways of cardiomyocytes. 16 During the apoptotic process, caspase-3 activation results in cleavage of cTn and subsequent release.
11 Different mechanisms explaining how cardiomyocytes could release cTnT have been suggested, 12 including membranous blebs enabling troponin to be released from cardiac cells because of ischemia alone without necrosis. 17 Elevation of circulating NT-proBNP is proportional to the extent of ventricular dysfunction in patients with or without overt HF. 18 There are few data demonstrating the association of NT-proBNP levels with both coronary Models were adjusted for variables significantly associated with biomarker levels at multivariate analysis, including oral antidiabetics/insulin and highsensitivity C-reactive protein for hs-cTnT and β-blockers and tryglicerides for NT-proBNP. CTA indicates computed tomographic angiography; hs-cTnT, highsensitivity cardiac troponin T; LVEF, left ventricular ejection fraction; and NTproBNP, N terminal pro brain natriuretic peptide. Relative effects of obstructive coronary stenoses and myocardial ischemia on high-sensitivity cardiac troponin T (hs-cTnT) and N terminal pro brain natriuretic peptide (NT-proBNP) plasma levels. Circulating levels of hs-cTnT and NT-proBNP are presented in patients subdivided according to (A) the absence of both obstructive coronary stenoses and ischemia (Normals), the presence of myocardial ischemia without obstructive coronary stenoses (Ischemia), the presence of obstructive coronary stenoses without myocardial ischemia (coronary artery disease [CAD]), and the presence of both (CAD+Ischemia) at separate analysis of computed tomographic angiography (CTA) and stress imaging; and (B) the absence or the presence of matched and unmatched findings at hybrid imaging analysis of CTA and myocardial perfusion imaging (MPI). atherosclerosis and myocardial ischemia in patients with stable CAD. 19, 20 Experimental and clinical studies 21, 22 have provided evidence that myocardial ischemia may cause per se an increased expression and secretion of natriuretic peptides by ventricular myocytes. In this study, both coronary atherosclerotic burden and presence of myocardial ischemia were predictors of higher NT-proBNP plasma levels in patients with stable CAD. However, in contrast to hs-cTnT, only the presence of myocardial ischemia was an independent predictor of elevated NT-proBNP. This association was mainly evident in males who had a higher prevalence of obstructive CAD and severe myocardial ischemia (Table IV in the online-only Data Supplement). Patients with obstructive coronary lesions and ischemia had significantly higher values of NT-proBNP than all other patients (Figure 3) . Interestingly, this subgroup of patients had also significantly decreased LVEF values as compared with all other patient groups ( Figure 4 ). Increased release of brain natriuretic peptide may be consequent to the effects of chronic repetitive ischemia on the myocardium, including both a direct stimulation of natriuretic peptide gene expression in the myocytes 22 and a mechanical stimulation induced by subclinical myocardial dysfunction with higher wall stress. 23 Independent of the mechanism, the current findings underline the relevance of circulating NT-proBNP as a marker of chronic ischemic coronary disease and are in agreement with the known prognostic role of this biomarker in patients with stable CAD. 6, 7 A schematic representation of the proposed mechanisms explaining the increased levels of hs-cTnT and NT-proBNP is reported in Figure 5 together with data from 2 representative patients with stable CAD.
Limitations
Assessment of ischemia was performed with varying modalities (positron emission tomography, single-photon emission computed tomography, stress echocardiography, or cardiac magnetic resonance imaging), which is a limitation but reflects the clinical reality (not every center applies the same diagnostic tests). Similarly, the definition of ischemic abnormalities included resting myocardial perfusion or wall motion defects compatible to some degree of scar. However, the main study findings were confirmed in the 193 patients with myocardial perfusion imaging and hybrid imaging where only inducible myocardial ischemia downstream a significant coronary lesion was considered.
The EVINCI protocol did not require evaluation of LV diastolic function. It cannot be excluded that some patients with multiple risk factors (hypertension, diabetes mellitus, obesity) had unrecognized heart failure with preserved ejection fraction and that this could have somewhat influenced NT-proBNP and hs-cTnT levels. 24, 25 In addition, another limitation includes that other troponin isoforms or degradation products 26 as well as other active BNP peptides 27 could have been measured extending our present understanding of the effects of the different patterns of atherosclerotic disease on both cardiac structure and endocrine function.
Conclusions
The present study provides evidence that circulating hscTnT and NT-proBNP levels, even if in the normal range, may provide different and complementary information on the presence and severity of CAD in patients with stable angina. Relative increase in circulating hs-cTnT is a marker of the coronary atherosclerotic process being related with the global atherosclerotic burden and with the type of atherosclerotic plaques. On the contrary, relative increase in circulating NT-proBNP is mainly associated with myocardial ischemia because of more severe coronary lesions and expresses a subclinical LV dysfunction possibly consequent to the chronic ischemic process. According to the present results, hs-cTnT and NT-proBNP may have a relevant clinical role in the screening process and in the prognostic stratification of patients with suspected CAD. Further studies are needed to assess whether these biomarkers can improve the accuracy of current diagnostic and prognostic predictive models and help to target personalized management in patients with stable angina.
Patients with stable coronary artery disease (CAD) represent a heterogeneous group in terms of their pathophysiological substrate, clinical presentation, and outcome. Circulating levels of high-sensitivity cardiac troponin T (hs-cTnT) and N terminal pro brain natriuretic peptide (NT-proBNP) are independent predictors of prognosis in patients with CAD. This is the first study which evaluated the relative effects of both coronary atherosclerosis and myocardial ischemia on cardiac release of hs-cTnT and NT-proBNP in patients with stable CAD, thus providing evidence that circulating hs-cTnT and NT-proBNP may provide different and complementary information on presence and severity of CAD. In particular, the features of coronary atherosclerosis are related with circulating hs-cTnT, also in the absence of ischemia; obstructive CAD causing myocardial ischemia is associated with increased levels of NT-proBNP. Accordingly, hs-cTnT and NT-proBNP may have a relevant clinical role in the screening process and in the prognostic stratification of patients with suspected CAD.
Significance
